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Abstract
Background: The cost-effectiveness of human papillomavirus (HPV) vaccination in women pre-sexual debut has
been demonstrated in many countries. This study aimed to estimate the cost-effectiveness of a 3-dose bivalent HPV
vaccination at ages 12 to 55 year in both rural and urban settings in China.
Methods: The Markov cohort model simulated the natural history of HPV infection and included the effect of
screening and HPV vaccination over the lifetime of a 100,000 female cohort. Transition probabilities and utilities
were obtained from published literature. Cost data were estimated by Delphi panel using healthcare payers’
perspective. Vaccine cost was assumed Hong Kong listed price. Vaccine efficacy (VE) was based on the PATRICIA trial
data assuming VE irrespective of HPV type at all ages on incident HPV. Costs and outcomes were discounted at 3 %.
Cervical cancer cases and incremental cost-effectiveness ratio (ICER) for vaccination and screening compared with
screening alone were estimated for each vaccination age. Reduced VE in women post-sexual debut were investigated
in scenario analyses.
Results: With 70 % vaccination coverage, a reduction of cancer cases varying from 585 to 33 in rural and 691 to 32
in urban were estimated at ages 12 to 55, respectively. The discounted ICERs of vaccination at any age under 23 years
in rural and any age under 25 years in urban were lower than the current threshold. Scenario analyses with lower VE
post-sexual debut confirmed the results with age 20 in rural and 21 in urban had consistent lower ICERs. The more
‘catch-up’ cohorts vaccinated at the start of a program, the more cancer lesions are avoided in the long-term.
Conclusions: Vaccination at any age under 23 years old in rural and any age under 25 years old in urban were
cost-effective. Catch-up to the age of 25 years in rural and urban could still be cost-effective.
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Background
Cervical cancer (CC) is an important cause of morbidity
and mortality among Chinese women. It is estimated the
age-standardized incidence and mortality rates were 7.5
and 3.4 per 100,000 women in China in 2012, lower than
corresponding world statistics, 14.0 and 6.8 per 100,000
[1]. However, given the large population base, China
accounted for 11.7 % (62,000 new cases) of the world’s
annual CC cases and 11.3 % (30,000 deaths) of the
world’s annual CC deaths [1]. Although organized
screening programs can reduce the cervical cancer
burden through early detection and treatment of pre-
cancerous lesions, the effectiveness of cervical cancer
screening in China is compromised due to dysfunctional
health care infrastructure, national screening program
being only been made accessible to a limited population
in rural China, and wide disparities in access to health
care in rural areas.
A new opportunity to reduce preventable deaths from
cervical cancer is the use of HPV vaccination. Two
prophylactic HPV vaccines are available since 2007 and
have high efficacy (>90 %) for preventing high-grade cer-
vical lesions associated with HPV-16 and HPV-18 [2–3].
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So far, there are more than 160 countries which have
approved the prophylactic vaccines and many have grad-
ually introduced the vaccines into the national routine
immunization program [4]. To date, phase III clinical
trials on a 3 doses of bivalent HPV vaccination (3DBV)
have been ongoing for over 7 years in mainland China
[5]. Though at this stage, it is uncertain whether a full-
scale initiative to vaccinate girls in China will be avail-
able [6], we expect that it will be approved by the State
Food and Drug Administration in the foreseeable future.
The constant growth of healthcare demand, in an
economic context characterized by limited resources,
requires that the decision-making process is based on
the comparison of alternative choices [7]. The World
Health Organization (WHO) recommends that the
cost-effectiveness of introducing a new vaccine to the
national immunization program is considered before
such a strategy is implemented [8], and has reiterated
this advice for the case of HPV vaccination [9]. To date,
epidemiological and economic models to determine the
cost-effectiveness of HPV vaccines have been used by
government policy-makers in many countries. Cost-
effectiveness analysis based on modelling studies can
integrate currently available clinical data with country-
specific epidemiological data to evaluate the potential
long-term impact of adding vaccination to screening [10].
To inform policy-making around HPV 16/18 vaccination,
multiple studies have been done in different countries
exploring the health and economic significance of HPV
vaccination [11–15], and consistently shown introduc-
tion of an HPV vaccine could be cost-effective com-
pared with current practice, even though incremental
cost-effectiveness varies widely with varying degrees of
complexity and transparency of each model [16].
Our previous research have already estimated the
incremental clinical and economic impact of HPV vac-
cination in addition to screening compared with screen-
ing intervention in rural and urban settings in China.
However, important questions remain about how HPV
vaccine should be used at population level. For example,
what is the optimal age range for vaccination, and
whether a catch-up vaccination campaign should accom-
pany the introduction of routine vaccination?
This economic study assumed a large age range from
12 to 55 years to evaluate the impact on the number of
cervical cancer and incremental cost-effectiveness ratio
(ICER) when adding vaccination to the current screening
strategies in China. This wide age range allowed us to
identify the age after which vaccination was no longer
cost-effective. Since there is wide disparity in cervical
cancer incidence and mortality, and unequal availability
of health care services between rural and urban areas in
China, our assessment will be based on a Markov cohort
model adapted to each setting to evaluate lifetime costs
and effectiveness of vaccinating girls aged 12 to 55. In such
context, we propose to estimate the cost-effectiveness of a
3-dose bivalent HPV vaccination (3DBV) versus current
screening practices at ages 12 to 55 years in both rural and
urban settings in China.
Methods
Model design
The model is a lifetime Markov cohort model (Additional
file 1: Figure S1) developed in Microsoft Excel software,
based on a previously published model [17]. It consisted of
a series of health states in which subjects were located and
between which they moved throughout the disease process,
reflecting the (simplified) natural history of oncogenic HPV
infection to CC.
The Markov model has a cycle time of 1 year and run
over life-time according to the mortality rate for women
reported by National Bureau of Statistics of China [18].
It consists of three modules: natural history, screening,
and vaccination. Overall, it contains 12 different health
states for each cycle within which transition occurs each
year governed by transition probabilities.
Data input
This study was approved by the Institutional Review
Board (IRB) of Cancer Institute and Hospital of Chinese
Academy of Medical Sciences (CICAMS) (Approval No.
13-066/742). The study population was a hypothetical
cohort of 12–55 year old girls. The parameters in this
modelling study were collected by expert consultation,
literature review and data extraction from previous stud-
ies conducted by CICAMS in summary forms, so no
individual patient information were involved, and in-
formed consent was exempted by CICAMS’ IRB. We
incorporated epidemiologic, clinical and economic data
in the model to replicate the development of cervical
cancer, and interventions such as vaccination, screening
and treatment. Major data inputs are showed in Table 1.
Some inputs are suited to both rural and urban settings,
such as vaccine efficacy, and transition probabilities
between states, while others are area-specific, such as
HPV infections among women, incidence and mortality
of cervical cancer, costs of screening and diagnosis and
treatment. We discriminated area-specific data for use in
two different scenarios.
Cost items
A cost study from a societal perspective with a micro-
costing approach had been conducted previously by our
team to estimate aggregated costs associated with CC
[19–21]. We updated that costs to reflect 2013 values
and consulted a Delphi panel [22] to confirm/validate/
modify the cost estimates. Given the particular situation
that most of the patients with diagnostically confirmed
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Table 1 Input data values for base case analysis
Parameter Base case value References
Rural Urban
Transition probabilities
No HPV to HPV 0-0.194 0-0.113 CICAMS pooled data base [30]
HPV to No HPV 0.32-0.61 0.32-0.61 CICAMS pooled data base [30]
HPV to CIN1 0.049 0.049 Moscicki 2001 [25]
CIN1 clearance 0.50 0.50 Van De Velde 2007 [26], Sanders 2003 [27]
CIN1 to CIN2/3 0.121 0.121 Van De Velde 2007 [26], Sanders 2003 [27]
CIN2/3 clearance 0.267 0.267 Melnikow 1998 [28]
CIN2/3 to cancer 0.128 0.128 Melnikow 1998 [28]
CC death rates 0.0699 0.0699 Quinn MA 2006 [29]
Cancer cured 0.212 0.212 Quinn MA 2006 [29]
Screening
Se of VIA/VILI 0.37-0.55 0.37-0.55 CICAMS pooled data base [30]
Se of Pap smear 0.48-0.52 0.48-0.52 Cuzick J 2006 [36]
Age at 1st screening 35 year 35 year Assumption
Age at 2nd screening 45 year 45 year Assumption
Screening coverage 6.25 % 21.5 % [38–40]
CIN1 treated 34 % 38 % Delphi panel [22]
CIN1 cured 100 % 100 % Delphi panel [22]
CIN2/3 treated 83 % 95 % Delphi panel [22]
CIN2/3 cured 90 % 90 % Delphi panel [22]
Unit costs(CNY)
Screening 24 CNY 54 CNY Delphi panel [22]
CIN1 treatment 367 CNY 681 CNY Delphi panel [22]
CIN2/3 treatment 2,626 CNY 4,237 CNY Delphi panel [22]
Cancer treatment 26,715 CNY 26,715 CNY Delphi panel [22]
Vaccine (3 doses) 1,900 CNY 1,900 CNY Hong Kong listed price
Vaccine administration (3 doses) 54 CNY 54 CNY WZ Yu 2006 [23]
Disutility scoresa
CIN1 detected 0.0128 0.0128 [31–35]
CIN 23 detected 0.0128 0.0128 [31–35]
Cancer treated 0.273 0.273 [31–35]
Cancer cured 0.062 0.062 [31–35]
Vaccine efficacyb
Against CC 93.2 % 93.2 % [3]
Against CIN2/3 64.9 % 64.9 % [3]
Against CIN1 50.3 % 50.3 % [3]
General variables
Discount rate 3 % 3 % [43]
Age at vaccination (years) 12-55 12-55 Assumption
a Health states No HPV, HPV, CIN 1 undetected and CIN 2/3 undetected have utility = 1 (i.e. no disutility); health states death and death from cervical cancer have
utility = 0; b Irrespective of type
Se sensitivity; CIN cervical intraepithelial neoplasia; HPV human papillomavirus; CC cervical cancer; VIA/VILI visual inspection with acetic acid/ iodine
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CC would seek for treatment in the urban hospitals,
only the treatment cost of CC in urban areas were
investigated.
The two round Delphi panel, selecting 6 rural and
12 urban clinical gynecologists and epidemiologists
from 8 provinces of China, was conducted to assess
the costs of screening and treatment, the proportion
of patients undergoing the treatment procedure for
cervical intraepithelial neoplasia (CIN) and CC. The
8 provinces were chosen from Northern (Beijing,
Tianjin, Liaoning), Central (Henan, Shanxi, Jiangsu),
Western (Xinjiang) and Southwestern (Chengdu) of
China. The two round panels lasted from August
2013 to December 2013 via written questionnaires.
Since HPV vaccine has not been marketed in China,
Hong Kong listed price (1900 CNY/3 doses) was used.
In addition, we assumed the HPV vaccine could be
added into current existing vaccine systems. Introducing
a new type of vaccine into national immunization pro-
gram can make use of existing personnel, equipment,
cold chain management, and other management system
and don’t need to build new systems. So we just need to
consider the increased cost (marginal cost). The cost of
HPV vaccine administration was calculated based on the
marginal cost of introducing hepatitis B vaccine into
China’s expanded programme on immunization, includ-
ing the employee compensation, surveillance, propa-
ganda, training, supervision, transportation, cold chain
and other equipment that were related to the vaccine
injection. The incremental vaccine administration cost
for an additional dose of hepatitis B vaccine was 17.93
CNY/per child [23]. Finally, we estimated a total of 54
CNY (17.53 × 3 doses ≈ 54) as the administration fee for
3-dose HPV vaccination in the current model. And we
found what we estimated from the existing HBV vaccin-
ation program (54 CNY) was consistent with the data
from Cameroon [24], one of the developing countries,
where the administrative cost of HPV vaccine was 8
USD (equivalent to 50 CNY) per 3 doses.
Transition probabilities and utilities
Data related to the natural history of the disease were
derived from literature review [25–29] or calculated
from the CICAMS pooled database of 17 population-
based studies [30]. The 17 population-based studies
included cervical cancer screening studies done in main-
land China from 1999 to 2008 with 30,371 women from
various parts of China. In this database, every woman
had the results of HPV testing recorded, and the screen-
ing positive women had the biopsy results included
which enabled us to calculate the transition probabilities
in natural history. Utilities were obtained from published
literature [31–35].
Screening practice and screening coverage
Currently, Chinese cervical cancer screening program in
rural areas sponsored by the government uses VIA/VILI
or Pap smear as the primary screening method. In urban
areas, most screenings are based on opportunistic exam
or through employment-based physical exam using Pap
smear. Therefore, we estimated 2/3 of screened women
undergoing the Pap smear and the 1/3 undergoing the
VIA/VILI in rural areas. In urban areas, we assumed all
screened women undergoing Pap smear by the Delphi
expert review panel [22]. Sensitivity of VIA/VILI was
calculated from the CICAMS pooled database of 17
population-based studies [30], and sensitivity of Pap
smear was published data from literature [36]. Both
screening scenarios in rural and urban assume twice in a
lifetime screening, one at 35 years and one at 45 years
according to WHO guidelines on cervical screening in
developing countries [37].
A 21.5 % screening coverage in urban areas was
assumed as reported in the Human Papillomavirus and
Related Cancers, Summary Report Update [38]. From
2012 to 2015, Chinese government is planning to screen
about 10 million women in rural areas every year [39].
There were about 1.60 billion women aged 35–64 in
rural China according the Sixth National Population
Census [40]. So we assumed 6.25 % screening coverage
in rural areas in China.
Vaccine efficacy and vaccine coverage
In the base case analysis, based on the results of the 4-
year end of study analysis of the randomised, double-
blind PATRICIA trial among HPV naïve girls, a 93.2 %,
64.9 %, 50.3 % overall efficacy against CC, cervical
intraepithelial neoplasia 2 or worse (CIN2+), CIN1+
irrespective of types was assumed in the model as a
proxy for vaccine effectiveness [3]. For scenario analysis,
the effect of a lower VE post-sexual debut was estimated.
The lower VE post-sexual debut was assumed as the
lower limit of 95 % Confidence Interval (CI) of the
reported VE. A cut-off age of 22 years in rural and
21 years in urban was selected to differentiate between
pre- and post-exposure based on the median age of
sexual debut age in all age groups in China [41].
The vaccination coverage was assumed as 70 %
according to the hepatitis B vaccination uptake at three
years after the availability of hepatitis B vaccination in
China [42].
Discount rate and study perspective
A 3 % discount rate was used according to the WHO
guidelines [43]. We used the same discount rate for
health outcomes and cost for analytical purpose.
The model essentially considered the perspective of the
health care payer and included only direct medical costs.
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Outcome measures
The main outcome measure used in the model was CC
cases and the incremental cost/ quality-adjusted life-years
(QALY). According to the recommendation of WHO, a
strategy is ‘cost-effective’ when the ICER falls between 1
and 3 times per capita national gross domestic product
(GDP) of the country [44]. As there is no GDP for rural
and urban areas reported separately in China, the thresh-
old for ICER was assumed to be the 3x national GDP
2013 (125,723 CNY) [45].
Model validation
The model was validated by comparing the age-specific
incidence and mortality of CC in rural and urban China
from the model with the ones reported by the National
Office for Cancer Prevention and Control [46]. Calibration
was performed by adjusting the transition probabilities
from persistent CIN2/3 to cervical cancer as well as tran-
sition probability to cancer death.
Base case analysis
The base case analysis was performed on the two mod-
elled cohorts of 12 to 55 years old girls, one cohort
assuming to receive an HPV vaccination program with a
70 % coverage and screening, the other cohort assuming
to receive only screening. In the regular base case ana-
lysis, only girls at one certain age would be vaccinated.
For instance, vaccination at age 12 means that only the
cohort of 12-year-old girls could be vaccinated; and vac-
cination at age 54 means that only the cohort of women
aged 54 could be vaccinated. The vaccine efficacy was
assumed constant across ages in base case analysis. The
main outcome considered was CC cases prevented and
the incremental cost per QALY gained for the vaccinated
cohort compared with the non-vaccination cohort at
ages 12 to 55 year in both rural and urban in China.
Scenario analysis
The HPV-16/18 vaccine had efficacy against infection
with HPV-16/18, with higher point estimates in the
HPV naïve than in the women with HPV infection [3].
So, the effect of lower vaccine efficacy with post-sexual
debut was explored. The lower VE was assumed as the
lower limit of 95 % CI of the reported VE.
Catch up analysis
The other was a catch-up program with additional vac-
cination cohorts up to age 25. An incremental approach
was used to estimate the effect of catch-up scenario, that
is, the vaccination of a 12-year-old cohort was compared
with a supplementary annual vaccinated cohort in a
stepwise manner to the final added vaccination cohort
was 25 year old. In other words, regular vaccination
would be conducted in the cohort of girls at age 12, and
catch-up would be given to the cohorts of females older
than age 12. The vaccination coverage rate for each
supplementary cohort was fixed at 70 % [42].
Results
Model validation
The results showed that the cancer incidence and mortal-
ity that produced by the Markov model were consistent
with the ones reported by the National Office for Cancer
Prevention and Control. Pearson’s correlation analysis was
done for incidence and mortality validation. The results
showed that the curves of model simulation had no
significance with the ones from cancer registry (r = 0.985,
0.973, 0.954 and 0.952 for rural incidence, urban inci-
dence, rural mortality and urban mortality respectively)
(Additional file 2: Figure S2).
Base case analysis
The effect of HPV vaccination on CC cases of 100,000 girls
and women at ages 12 to 55 was shown in Fig. 1. With
Fig. 1 Effect of age at vaccination on cases of CC averted. (a: rural; b: urban)
Liu et al. BMC Cancer  (2016) 16:164 Page 5 of 11
70 % vaccination coverage, a reduction of CC cases over
the lifetime of the cohort varying from 585 to 33 in rural
and 691 to 32 in urban were estimated at ages 12 to 55, re-
spectively. For example, CC cases prevented in rural and
urban was about 61 % when vaccinating at age 12 year old
girls (vaccine coverage: 70 %, VE on CC: 93.2 %), while an
estimated 22 %, 23 % of CC cases were avoided when vac-
cinating at age 40. The figure clearly shows that the reduc-
tion of CC cases was the largest when vaccinating at early
ages but the effectiveness was still substantial at later ages.
Figure 2 showed the effect of vaccination age on ICER
in rural and urban settings. The results indicated that the
estimated ICER of adding vaccination to current screening
was lower when vaccinating at younger ages. The undis-
counted ICER was the most cost-effectiveness when vac-
cination occurs at age 12. However, the discounted results
show the lowest ICER was found at the age of 14. The dis-
counted ICER results also indicating that HPV vaccination
program in girls was cost-effective at any age under 23 in
rural and 25 in urban setting under current threshold.
Scenarios analysis
Scenario analyses with lower VE post-sexual debut con-
firmed that vaccination remained cost-effectiveness at
any age under 20 in rural and 21 in urban, because the
ICER was lower than the current threshold, and also
indicated that the earlier vaccination was received, the
better discounted ICER value was reached at age 14 in
rural and urban (Fig. 3).
Catch up analysis
Figure 4 illustrated the reduction of CC cases due to vac-
cination in rural and urban. Maximal vaccination reduction
of CC cases due to vaccination reached 30 years after vac-
cination. The additional vaccination cohorts substantially
decreased the number of CC cases in both rural and urban
settings. The more 'catch-up' cohorts vaccinated, the more
CC cases are avoided over the lifetime of the cohorts.
Figure 5 showed the discounted and undiscounted ICER
of adding each age vaccination cohort year by year up to
age 25. Routine vaccination in 12-year-old girls and a
catch-up to age 25 years could still be cost-effective in
both rural and urban areas.
Discussion
To date, epidemiological and economic models to deter-
mine the cost-effectiveness of HPV vaccination have been
used by government policy-makers for policy deliberations
Fig. 2 Effect of vaccination age on ICER in rural (a) and urban (b) China
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Fig. 3 Scenarios analysis - Effect of age at vaccination on ICER in rural (a) and urban (b)
Fig. 4 Total CC cases number in vaccinated cohorts 12 to 25 in rural (a) and urban (b). (12 = vaccinate age 12 only and ages 13–25 not
vaccinated; 12–15 = vaccinate ages 12–15 and ages 16–25 not vaccinated; 12–20 = vaccinate ages 12–20 and ages 21–25 not vaccinated;
12–25 = vaccinate ages 12–25)
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and professional guidelines in many countries. To our
knowledge, the present study was the first analysis to
assess the effect of vaccination age from 12 to
55 years on cost-effectiveness of HPV vaccination in
addition to screening compared with the current
screening situation of cervical cancer in China. The
evaluation was based on a Markov cohort model
adapted to rural and urban settings, simulating the
lifetime costs and effects of vaccinating 12 to 55 years
old girls and women.
From our study, HPV 16/18 vaccination of younger
girls could substantially decrease more CC cases than
older women. Vaccination at 12 years old can prevent
about 60 % CC cases, whereas vaccination at age 40 can
only avert 20 % CC cases. Maximal reduction of CC
cases occurred 30 years after vaccination, and the more
'catch-up' cohorts were vaccinated, the more CC cases
were avoided in the long-term period. Our findings were
consistent with the general consensus that the effective-
ness of HPV vaccination decreasing with increasing age
of vaccination [10, 31]. Several studies conducted in
Europe, North America, South America and Portland
indicated that the adolescence and early adulthood had
the highest prevalence of HPV infection [47]. 55 % ado-
lescents would be infected by HPV within three years
after the sexual debut [25]. Young girls benefit most
from a prophylactic vaccine before sexual debut. How-
ever, a study included a total of 30,371 women from 17
population-based studies throughout China found that
the rates of oncogenic HPV infection are high among
women aged 35–39 years in rural and aged 40 or older
in urban [48]. Studies in other countries also demon-
strated that women over 25 year old still had risks of
high HPV incidence [49–51]. Furthermore, immunogen-
icity data following vaccination with the HPV-16/18
vaccine showed that an age-dependent decrease in anti-
body titers was observed with increasing age, titers in
the younger age group (15–25) remained at least 5-fold
higher than those in 46-to-55-year-old women, however,
absolute values were high in all age groups, titers in the
oldest age group (46–55) remained at least 8-fold
higher than those associated with natural infection in
15- to 25-year-old women [52]. In our study, we could
conclude that women at all ages will benefit from
prophylactic HPV vaccination, but the benefit propor-
tion decreased with age. Rationally, cost-effectiveness
must be taken into account when considering HPV
vaccination in older women.
The undiscounted data showed cost-effective of HPV
vaccination were more favourable at earlier ages of vac-
cination. Vaccination targeting older girls who may have
been infected previously with HPV 16 or 18 may show
less benefits compared with young adolescents who have
not yet been exposed to HPV [53]. However, the dis-
counted data showed that the most favourable ICER was
found at the age of 14 in both rural and urban. That
may be because shifting the vaccination to a time closer
to the moment of infection will slightly improve the
cost-effectiveness results when discounting is applied.
Vaccinating at an earlier age involves a longer waiting
period before the health effects of the vaccine become
apparent compared with vaccinating at an older age
[31]. In addition, we found that HPV vaccination pro-
gram in girls before age 23 in rural and 25 in urban
maintained cost-effective at the price of approximately
100 US dollars (1900 CNY per course) for the CC pre-
vention in China. Recently, several clinical trials have
shown that not only HPV vaccination of young teenage
girls but also vaccination of older girls and women induces
high virus-neutralizing antibody titers [52, 54]. We found
that catch up program for ages 12–25 years in rural
and urban were still cost-effective for a threshold of 3
times national GDP/capita, assuming the vaccine cost per
dose was approximately 100 USD. Several countries elected
to fund temporary catch-up programs for females up to
ages 16 or 18 years (e.g., United Kingdom) and, in fewer
countries, up to age 26 years (e.g., Australia) [55]. An alter-
native approach has been suggested in Italy where
Fig. 5 The impact of catch up cohorts on the ICER (a: rural; b: urban). (12 = vaccinate age 12 only; 12–15 = vaccinate ages 12 and catch-up from
13–15; 12–16 = vaccinate ages 12 and catch-up from 13–16; 12–18 = vaccinate ages 12 and catch-up from 13–18, etc.)
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concurrent vaccination of 3 cohorts (ages 11, 18 and
25 years) is a more cost-effective strategy in reducing
HPV-related cervical diseases among Italian women.
However, several studies that have assessed catch-up and
routine HPV vaccination programs have found that vac-
cinating beyond age 22 years is not cost-effective [56–58].
In the U.S., it was proven that HPV vaccination of older
women participating in the screening program provides
much lower benefits than vaccination of pre-adolescent
girls and does not provide good health value for the
resources invested, compared with well-accepted health
interventions [59]. Explanation for the differences between
model analyses have been discussed and are generally
attributed to model assumptions, such as the amount
of prior exposure to HPV, natural immunity assump-
tions, transmission dynamics, and vaccine characteris-
tics (e.g., protection among those with prior exposure
and cost per dose). A PRIME modelling study [60]
assessed differences between countries in terms of
cost-effectiveness and health effects, which found that
although large between-country disparities exist for
HPV vaccination, the effect and cost-effectiveness of
vaccinating girls before sexual debut at high coverage
can be reasonably predicted from important parame-
ters, such as data for cancer incidence, distribution of
HPV type in cancer, and vaccination costs.
The study has limitations. Firstly, the model is a static
cohort model, which does not capture the indirect pro-
tection resulting from immunization (herd-protection
effects). It could not analyse the benefits of herd immun-
ity caused by the reduction of circulation of the infective
agent. As a result, the benefits of the vaccination could
be underestimated. Secondly, one of the uncertainties
we had was whether HPV type replacement took place
once vaccination against HPV-16/18 was widespread.
The prevalence of HPV-16/18 may fall to very low levels
with vaccination. Other oncogenic HPV subtypes cur-
rently responsible for relatively few CC case, might fill
the niche left by HPV-16/18. To date, most vaccine trials
have not seen significant increases in prevalence of non-
vaccine types [61], and type replacement is not likely
because HPV types were found to occur randomly and
to lead to cervical disease independently [62]. Even if
type replacement is observed, it may not have important
public health implications because HPV 16 and HPV 18
pose much higher cancer risks than other types [63].
The model currently assumed a limited level of replace-
ment by other HPV types. Thirdly, we ignored the effect
of natural immunity, because antibodies induced by
natural infections are not always protective [51]. Women
who have had a previous infection and developed detect-
able antibody levels may still be at risk of subsequent
infections. Lastly, the present model only included cer-
vical cancer and did not take into account vulvar cancer,
vaginal cancer, anal and some proportion of oropharyn-
geal cancer that the HPV vaccine may have efficacy in
preventing [64–66]. Should these diseases be included in
the evaluation, the protection offered by HPV vaccin-
ation would be wider, and could lead to a lower ICER
than the present analysis. These results are thus likely to
provide conservative estimates.
Conclusion
We conclude that 14 years old maybe the most favourable
vaccination age in rural and urban, and a bivalent HPV
vaccination program in girls before age 23 in rural and 25
in urban setting was shown to be cost-effective strategies
for the prevention of CC in China. Catch-up programmes
that extend to age 25 years in rural and urban could still
be cost-effectiveness.
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